| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality
|
Palumbo, Carlotta
|
|
|
18 |
4 |
p. 314-321.e1
|
artikel
|
| 2 |
A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806)
|
Isfahanian, Naghmeh
|
|
|
18 |
4 |
p. e410-e415
|
artikel
|
| 3 |
Chemoradiation for Management of Locally Recurrent or Residual Bladder Cancer: A Case Series and Review of the Literature
|
Ballas, Leslie
|
|
|
18 |
4 |
p. e473-e477
|
artikel
|
| 4 |
Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma
|
Wells, J. Connor
|
|
|
18 |
4 |
p. e350-e359
|
artikel
|
| 5 |
Clinical Outcomes of Patients With Histologic Variants of Urothelial Carcinoma Treated With Selective Tetramodal Bladder-preservation Therapy Incorporating Consolidative Partial Cystectomy
|
Kijima, Toshiki
|
|
|
18 |
4 |
p. 268-273.e2
|
artikel
|
| 6 |
Combination of Platelet-Lymphocyte Ratio and Monocyte-Lymphocyte Ratio as a New Promising Prognostic Factor in Upper Tract Urothelial Carcinoma With Large Tumor Sizes > 3 cm
|
Jan, Hau-Chern
|
|
|
18 |
4 |
p. e484-e500
|
artikel
|
| 7 |
Corrigendum
|
|
|
|
18 |
4 |
p. e416-e417
|
artikel
|
| 8 |
Editorial Board
|
|
|
|
18 |
4 |
p. A10
|
artikel
|
| 9 |
Effect of CXCL12 and Its Receptors on Unpredictable Renal Cell Carcinoma
|
Floranović, Milena Potić
|
|
|
18 |
4 |
p. e337-e342
|
artikel
|
| 10 |
Effects of Bladder Cancer on UK Healthcare Costs and Patient Health-Related Quality of Life: Evidence From the BOXIT Trial
|
Cox, Edward
|
|
|
18 |
4 |
p. e418-e442
|
artikel
|
| 11 |
Efficacy and Effect of Cabozantinib on Bone Metastases in Treatment-naive Castration-resistant Prostate Cancer
|
Smith, David C.
|
|
|
18 |
4 |
p. 332-339.e2
|
artikel
|
| 12 |
First-line Treatment of Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: Systematic Review and Network Meta-analysis
|
Monteiro, Fernando Sabino M.
|
|
|
18 |
4 |
p. 244-251.e4
|
artikel
|
| 13 |
Has Stage Migration in Renal Cancer Run Its Course? A SEER Database Analysis
|
Haifler, Miki
|
|
|
18 |
4 |
p. e368-e373
|
artikel
|
| 14 |
HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter
|
Yorozu, Takashi
|
|
|
18 |
4 |
p. e443-e449
|
artikel
|
| 15 |
Medicaid Expansion Did not Improve Time to Treatment for Young Patients With Metastatic Renal Cell Carcinoma
|
Desai, Anuj S.
|
|
|
18 |
4 |
p. e386-e390
|
artikel
|
| 16 |
Metastasis, Mortality, and Quality of Life for Men With NCCN High and Very High Risk Localized Prostate Cancer After Surgical and/or Combined Modality Radiotherapy
|
Tward, Jonathan D.
|
|
|
18 |
4 |
p. 274-283.e5
|
artikel
|
| 17 |
METastasis Reporting and Data System for Prostate Cancer as a Prognostic Imaging Marker in Castration-resistant Prostate Cancer
|
Yoshida, Soichiro
|
|
|
18 |
4 |
p. e391-e396
|
artikel
|
| 18 |
Neuroendocrine Carcinoma of the Urinary Bladder: A Large, Retrospective Study From the French Genito-Urinary Tumor Group
|
Sroussi, Marine
|
|
|
18 |
4 |
p. 295-303.e3
|
artikel
|
| 19 |
Phase 2 Study of Seviteronel (INO-464) in Patients With Metastatic Castration-Resistant Prostate Cancer After Enzalutamide Treatment
|
Madan, Ravi A.
|
|
|
18 |
4 |
p. 258-267.e1
|
artikel
|
| 20 |
Plasma Circulating Tumor DNA and Clonal Hematopoiesis in Metastatic Renal Cell Carcinoma
|
Bacon, Jack V.W.
|
|
|
18 |
4 |
p. 322-331.e2
|
artikel
|
| 21 |
Prognostic Significance of Inflammation-associated Blood Cell Markers in Nonmetastatic Clear Cell Renal Cell Carcinoma
|
Lee, Alvin
|
|
|
18 |
4 |
p. 304-313
|
artikel
|
| 22 |
Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis
|
Mori, Keiichiro
|
|
|
18 |
4 |
p. e402-e409
|
artikel
|
| 23 |
Real World Experience With Pembrolizumab in Recurrent or Advanced Prostate Cancer
|
Higa, Julianna
|
|
|
18 |
4 |
p. e397-e401
|
artikel
|
| 24 |
Renal Function Impairment Below Safety Limits Correlates With Cancer-specific Mortality in Localized Renal Cell Carcinoma: Results From a Single-center Study
|
Antonelli, Alessandro
|
|
|
18 |
4 |
p. e360-e367
|
artikel
|
| 25 |
Renal Neuroendocrine Neoplasms: A Single-center Experience
|
McGarrah, Patrick W.
|
|
|
18 |
4 |
p. e343-e349
|
artikel
|
| 26 |
Risk for Venous Thromboembolic Events in Patients With Advanced Urinary Tract Cancer Treated With First-Line Chemotherapy
|
Bamias, Aristotelis
|
|
|
18 |
4 |
p. e457-e472
|
artikel
|
| 27 |
Sunitinib Versus Sorafenib as Initial Targeted Therapy for mCC-RCC With Favorable/Intermediate Risk: Multicenter Randomized Trial CROSS-J-RCC
|
Tomita, Yoshihiko
|
|
|
18 |
4 |
p. e374-e385
|
artikel
|
| 28 |
Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities
|
Luzzago, Stefano
|
|
|
18 |
4 |
p. e450-e456
|
artikel
|
| 29 |
Table of contents
|
|
|
|
18 |
4 |
p. A13-A18
|
artikel
|
| 30 |
The Efficacy of Lenvatinib Plus Everolimus in Patients with Metastatic Renal Cell Carcinoma Exhibiting Primary Resistance to Front-Line Targeted Therapy or Immunotherapy
|
Hamieh, Lana
|
|
|
18 |
4 |
p. 252-257.e2
|
artikel
|
| 31 |
The 2020 Kidney Cancer Treatment Sequence Issue
|
Hsieh, James J.
|
|
|
18 |
4 |
p. 241-243
|
artikel
|
| 32 |
The Role of Metastasectomy in Urothelial Carcinoma: Where Are We in 2020?
|
Lemke, Emily
|
|
|
18 |
4 |
p. e478-e483
|
artikel
|
| 33 |
Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States
|
George, Daniel J.
|
|
|
18 |
4 |
p. 284-294
|
artikel
|
Tijdschrift beschrijving